^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600E + PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-ra
    Entrez ID:
    29126; 673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    6d
    Prognostic analysis and expression patterns of programmed cell death ligand 1 and BRAF V600E in esophageal neuroendocrine carcinoma. (PubMed, Oncol Lett)
    In conclusion, BRAF V600E and PD-L1 were more frequently expressed in the MiNEC-SCC compared with small cell neuroendocrine carcinoma. Surgery and postoperative adjuvant therapy were notably associated with improved PFS.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF V600E • BRAF V600 • BRAF V600E + PD-L1 expression
    over3years
    Development of a novel approach for multiparametric characterization of CTCs from colorectal cancer (EACR 2022)
    Post-surgery samples revealed an increase of CTCs in 55.6% (5/9) of patients and changes in CTC subpopulations responded to 3 models: gain of PD-L1; gain of PD-L1 and BRAFV 600E or loss of both markers. Conclusion We optimized an antibody panel to evaluate BRAF V600E and PD-L1 expression on CTCs from early-stage CRC patients and we developed an efficient automatic analysis method, highlighting the importance of evaluating multiple parameters such as size, expression levels or protein localisation to identify intra and inter individual tumour heterogeneity.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF V600E • BRAF V600 • BRAF V600E + PD-L1 expression